|Home | About | Journals | Submit | Contact Us | Français|
Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
Chikungunya virus (CHIKV) has infected millions of people in Africa, Europe, and Asia1,2 since its re-emergence in Kenya in 2004. The severity of disease and spread of this epidemic virus present a serious public health threat in the absence of vaccines or anti-viral therapies. Here, we describe a novel vaccine that protects against emerging CHIKV infection of non-human primates (NHP). We show that selective expression of viral structural proteins gives rise to virus-like particles (VLPs) in vitro that resemble replication-competent alphaviruses. Immunization with these VLPs elicited neutralizing antibodies against envelope proteins from different CHIKV strains. Monkeys immunized with VLPs produced high titer neutralizing antibodies that protected against viremia after high dose challenge. We transferred these antibodies into immunodeficient mice, where they protected against subsequent lethal CHIKV challenge, establishing a humoral mechanism of protection. Immunization with alphavirus VLP vaccines represents a strategy to contain the spread of CHIKV and related pathogenic viruses in humans.
Chikungunya virus (CHIKV), a mosquito-borne alphavirus in the family Togaviridae, was first isolated in Tanzania in 19523. Infection by this virus in humans is characterized by rash, high fever and, its hallmark feature, severe arthritis that can persist for years1,2. An epidemic strain of CHIKV appeared on Reunion Island in 2005 and has since spread to more than 18 countries4 (see also http://www.cdc.gov/ncidod/dvbid/chikungunya/CH_GlobalMap.html). Dissemination of this epidemic virus is associated with genetic mutations that facilitate adaptation to a new insect vector, the Asian tiger mosquito, Aedes albopictus5, that survives in temperate climates and is widely distributed6. CHIKV continues to cause substantial morbidity resulting in significant economic losses, and vaccine development remains a high priority.
CHIKV is composed of a positive single strand genomic RNA of 12,000 nucleotides encoding four nonstructural and five structural polyproteins7. The nonstructural proteins, nsP1, nsP2, nsP3 and nsP4, are required for virus replication; the structural proteins, which consist of capsid (C) and envelope proteins (E; E1, E2, E3 and 6K), are synthesized as polyproteins and are cleaved by capsid autoproteinase and signalases7 (Fig. 1a, upper panel). Based on the similarity of CHIKV to other alphaviruses, CHIKV has spikes on the virion surface that are each formed by three E1-E2 heterodimers8,9, where the E1 glycoproteins mediate fusion and E2 glycoproteins interact with the host receptor7. Phylogenetic analysis of CHIKV has revealed three genotypes: Asian, East/Central/South African and West African. All strains are highly related, with 95.2–99.8% amino acid similarity10. Although CHIKV strains vary, individual strains are antigenically related, so it is potentially possible to design a vaccine that works against heterologous strains11.
We first analyzed the immunogenicity and cross-reactivity of two disparate strains, 37997 from the older West Africa lineage and LR2006 OPY-1, the more recent strain responsible for the current epidemic. To examine the specificity of viral cell entry and their sensitivity to neutralizing antibodies, we developed lentiviral vector reporters pseudotyped with glycoproteins from these different CHIKV strains. Such vectors allow analysis of the mechanism and the specificity of entry and serve to quantitate antibody neutralization more readily than wild type viruses that pose significant biohazard concerns for routine laboratory analyses. They therefore provide a useful tool for the study of CHIKV entry as well as for vaccine development12-14. We inserted CHIKV E genes expressing the native polypeptide, E3-E2-6K-E1 (Fig. 1a, lower panel), for the 37997 and LR2006 OPY-1 strains into an expression vector (E37997 and EOPY-1). Incorporation of the two CHIKV Es into the pseudotyped lentiviral vectors was verified by buoyant density gradient sedimentation of the virus. Both CHIKV E and HIV-1 Gag had the same buoyant density as lentivirus particles (Supplementary Fig. 1). The 37997 and LR2006 OPY-1 CHIKV pseudotyped lentiviral vectors infected several cell lines permissive for viral replication15 (Fig. 1b, left). We measured their ability to express a luciferase reporter in 293A human renal epithelial cells and found that entry was dose-dependent (Fig. 1b, right), while a control devoid of CHIKV envelope proteins did not infect these cell lines. To determine whether entry occurred through the same mechanism as native virus, we analyzed pH and endosome dependence of entry 13. CHIKV infects through pH-dependent cell fusion15; thus, addition of ammonium chloride or chloroquine, which prevents acidification of the endosome, caused a dose-dependent reduction in CHIKV pseudotyped vector entry (Fig. 1c). We observed similar inhibition of entry with VSV-G, known to enter in this fashion, but not with amphotropic murine leukemia virus (MuLV) glycoprotein 70, which enters by a pH-independent mechanism13,16. These findings demonstrated that lentiviral vectors pseudotyped with CHIKV envelope mediated entry through the same mechanism as wild type virus. Next, we examined a commercially available immune serum from mice infected with an established CHIKV strain (ATCC). Incubation of immune sera with the CHIKV pseudotyped lentiviral vector, but not a VSV-G pseudotyped vector, inhibited entry (Fig. 1d). The specificity and potency of neutralizing antibodies could therefore be quantified without exposure to infectious virus.
We analyzed eukaryotic expression vectors encoding C-E3-E2-6K-E1 from strains 37997 and LR2006 OPY-1 (C-E37997 and C-EOPY-1) for their ability to give rise to VLPs. We transfected 293T human kidney cells with plasmids C-E37997 or C-EOPY-1 or the E expression vectors described above, E37997 or EOPY-1 (Fig. 2a, upper panel), and confirmed expression in the cell lysates by Western blotting (Fig. 2a, lower panel). We also detected C and E1/E2 proteins in the supernatant by Western blotting after transfection of the C-E37997 or C-EOPY-1 vector, suggesting that CHIKV VLPs had been generated. We purified VLPs by buoyant density gradient sedimentation. The yield of VLPs from strain 37997 was 10–20 mg L−1 – approximately 100 times higher than that from strain LR2006 OPY-1. For this reason and because of the high degree of amino acid similarity among CHIKV strains, we used the 37997 strain to produce VLPs. Fractionation of clarified supernatant showed greatest incorporation of E1/E2 into the VLPs at a density of 1.2 g mL−1 (Fig. 2b, left), comparable to the density of wild type CHIKV17. Examination of the purified fraction from strain 37997 by electron microscopy revealed VLPs with the same morphologic appearance as wild type virus (Fig. 2b, right).
Cryoelectron microscopy and three dimensional image reconstruction, assuming icosahedral symmetry, showed that the VLPs had an external diameter of 65 nm and a core diameter of 40 nm (Fig. 2c). The potent immunogenic E1/E2 glycoproteins are organized into 240 heterodimers, assembled into 80 glycoprotein spikes arranged with T=4 quasi symmetry on the surface of the VLPs (Fig. 2c), closely similar to the structure of Sindbis virus (Supplementary Fig. 2; see also refs. 8,9,18).
Because of the ease of DNA vaccine preparation and its broad applicability, we compared the relative immunogenicity of plasmid DNA to VLP vaccines in mice by immunizing with DNA vaccines encoding C-E or E (strains 37997 and LR2006 OPY-1) or VLPs from strain 37997 (VLP37997) in the presence or absence of Ribi adjuvant. BALB/c mice injected twice intramuscularly with VLPs with adjuvant generated the highest titer neutralizing responses against both the homologous strain 37997 (Fig. 3a, right panel; IC50, 1:10,703) and the heterologous strain LR2006 OPY-1 (Fig. 3b, right panel; IC50, 1:54,600). While three immunizations with the plasmids encoding C-E and E from both strains elicited neutralizing responses, these titers were less than five percent those of VLP-immunized mice (Fig. 3a, b; left panel; IC50 titer of 319 for DNA C-E37997 against strain 37997; 525 for DNA C-E37997 against strain LR2006 OPY-1). These results suggested that VLPs elicited a more potent neutralizing antibody response than DNA vaccines.
To characterize VLP-induced immune responses in a model with stronger predictive value for humans, we immunized rhesus macaques with VLPs. Monkeys received intramuscular injections of VLP37997 or PBS alone as a control. We tested sera from immunized and control monkeys against CHIKV strain 37997 and LR2006 OPY-1 pseudotyped lentiviral vectors. All non-human primates (NHP) immunized with VLPs developed substantial neutralizing activity to both homologous and heterologous strains after primary immunization that increased after boosting (Fig. 3c; left panel: IC50 titer of 10,219 against strain 37997, right panel: IC50 titer of 15,072 against strain LR2006 OPY-1). Interestingly, there was slightly increased neutralization of LR2006 OPY-1 compared to 37997 in both mice and monkeys, although these effects were not substantial, suggesting that LR2006 OPY-1 may present a common epitope to the immune system somewhat better than 37997. To confirm that these antibodies neutralized infectious virus, we performed a plaque reduction neutralization test (PRNT) against the CHIKV LR2006 OPY-1. The antisera from the immunized monkeys elicited neutralizing antibody responses against LR2006 OPY-1 at PRNT50 titers of 40,133 (Fig. 3d). These data suggested that neutralizing antibodies using pseudotyped lentiviral vectors correlated with the PRNT assay, and that all VLP-immunized monkeys generated potent neutralizing antibody responses against CHIKV.
To establish the CHIKV challenge model in monkeys, we injected two naïve rhesus monkeys intravenously with a high titer LR2006 OPY-1 virus stock. Viremia commenced at 6 h and lasted until at least 72 h after challenge in these monkeys, with the peak viremia at 24 h after infection (Supplementary Fig. 3a). Similar to humans, infection in NHPs resulted in viremia and was not lethal. In addition, we observed a similar transient acute lymphopenia and a pro-inflammatory response as measured by transient neutrophilia and an increase in monocyte counts (Supplementary Fig. 3b). We assessed the ability of the VLP vaccine to protect against infection by intravenous challenge of monkeys immunized with VLPs or controls using the same high titer LR2006 OPY-1 virus stock 15 weeks after the final immunization. In this model, all immunized monkeys controlled the challenge virus completely (Fig. 4a). In contrast, we observed viremia in all the control monkeys injected with CHIKV, as in the pilot experiment. Similarly, monocyte counts were markedly increased in control monkeys 4 days after challenge, while they remained unchanged in vaccinated monkeys (Fig. 4b, Control, at day 0 vs. 7, P = 0.0015; VLPs at day 0 vs. 7, P = 0.38). These data suggest that immunization protected against both viremia and the inflammatory consequences of infection.
To define the mechanism of protection in these animals, we investigated whether or not immune IgG could protect against lethal challenge using an adoptive transfer model. Previous studies have shown that immunodeficient mice with defective type-I interferon signaling are susceptible to lethal CHIKV infection, displaying pathologic manifestations of infection19, and providing a model to evaluate immune mechanisms of protection. For example, Couderc et. al20 showed that antibodies play an important role in protecting against CHIKV infection by passive transfer of IgG from infected humans in this model. Here, we intravenously transferred purified total IgG from immunized or control monkeys into these mice, then challenged the recipient mice intradermally with a lethal dose of LR2006 OPY-1 24 h later. Recipients of purified IgG from CHIKV-immunized monkeys demonstrated no detectable viremia after challenge and were completely protected from lethality (Fig. 4c,d). In contrast, all mice that received purified IgG from control monkeys showed severe infection and viremia, and all died. These results indicate that humoral immune responses induced by CHIKV VLPs conferred protection against CHIKV infection.
To date, there has been limited success in developing a safe and effective CHIKV vaccine. A live attenuated CHIKV vaccine candidate21,22 caused transient arthralgia in volunteers23. Other efforts include a formalin-killed vaccine24,25, a Venezuelan equine encephalitis/CHIKV chimeric live attenuated vaccine26 and a consensus-based DNA vaccine27 that have not yet proven both safe and effective. Development of a safe and effective CHIKV vaccine will require additional evaluation in humans. However, the safety and efficacy of VLP vaccines in general make them promising candidates for further study.
VLPs are known to be highly immunogenic and elicit higher titer neutralizing antibody responses than subunit vaccines based on individual proteins28-30. Such VLPs authentically present viral spikes and other surface components in a repetitive array that effectively elicits recognition by B-cells to stimulate antibody secretion28,29. This recognition leads to B cell signaling and MHC class II up-regulation that facilitates the generation of high titer specific antibodies. VLPs from other viruses, including hepatitis B virus and human papillomavirus, elicit high titer neutralizing antibody responses that contribute to protective immunity in humans30,31. The vaccines described here represent the first use of recombinant VLPs to prevent infection by alphaviruses. At a time when there are no commercially available vaccines and CHIKV is emerging, it has the potential to significantly impact the spread of this disease. Changes in trade, travel and global climate have aided the spread of mosquito species worldwide, which may potentially cause other alphavirus outbreaks. This approach to vaccine development may prove useful for other alphaviruses of increasing concern, including Western, Eastern, and Venezuelan equine encephalitis viruses, o’nyong-nyong virus and Ross River virus.
We synthesized plasmids encoding structural polyproteins C, E1, E2, E3 and 6K (strains 37997 and LR2006 OPY-1, GenBank EU224270 and EU224268, respectively) as previously described14 (GeneArt). We amplified plasmids encoding the polyproteins E3, E2, 6K, and E1 by PCR using sense primer 5′-GCTCTAGACACCATGAGCCTCGCCCTCCCGGTCTTG-3′ and antisense primer 5′-TGGATCCTCATTAGTGCCTGCTAAACGACA-3′ (37997) and sense primer 5′-GCTCTAGACACCATGAGTCTTGCCATCCCAGTTATG-3′ and antisense primer 5′-TGGATCCTCATTAGTGCCTGCTGAACGACA-3′ (LR2006 OPY-1). We inserted XbaI and BamHI sites for cloning. We digested each fragment with XbaI/BamHI and inserted it into a eukaryotic expression vector, CMV/R14 (C-E37997, C-EOPY-1, E37997 and EOPY-1). The CMV/R vector comprises the human CMV IE enhancer/promoter, an HTLV-1 R region containing a splicing donor, a CMV IE splicing acceptor and bovine growth hormone poly A signal.
We created lentiviral vectors expressing glycoproteins from different CHIKV strains. The method for producing recombinant lentiviral vectors expressing a luciferase reporter gene has been previously described12,14. Briefly, we cotransfected 293T cells with 500 ng CHIKV E plasmid from either strain (E37997 or EOPY-1), 7 μg of a transducing vector encoding a luciferase reporter gene under the control of a CMV promoter (pHR’CMV-luciferase plasmid), and 7 μg of a packaging plasmid that expresses all human immunodeficiency virus type 1 (HIV-1) structural proteins except envelope (pCMVΔR8.2) (Supplementary Fig. 1a). Additional methods and neutralization assay with CHIKV E pseudotyped lentiviral vectors are described in the Supplementary Methods.
We transfected 293F cells (2.5 × 108) (Invitrogen) with 293fectin transfection reagent (Invitrogen) and 125 μg of C-E37997 plasmid following the manufacturer’s recommendations. Detailed methods for buoyant density gradient analysis and purification of VLPs have been described in a previous publication32 and in the Supplementary Methods.
We flash-froze Chikungunya VLPs on holey grids in liquid ethane, and recorded images at 47K magnification with a CM300 FEG microscope with electron dose levels of approximately 20 e−/Å2. We digitized all micrographs at 6.35 μm per pixel using a Nikon scanner, and boxed individual particle images using the program e2boxer in the EMAN2 package33. We used the CTFIT program from the EMAN package34 to determine CTF parameters and flip phases. We constructed an initial model in EMAN using assigned 2-, 3-, and 5-fold views and refined it in EMAN assuming icosahedral symmetry. The number of particles incorporated into the final reconstruction was 1489, giving a final resolution of 18 Å based on a 0.5 Fourier shell correlation threshold.
We mixed 19 μg of VLPs (equivalent to approximately 10 μg of E1/E2) in 60 μl normal saline with 60 μl of Ribi solution (Sigma Adjuvant system, Sigma-Aldrich) per mouse. We injected female 6- to 8-week-old BALB/c mice in the right and left quadriceps muscles with VLPs in normal saline or Ribi in 120 μl total volume, two times at weeks 2 and 6. For DNA vaccination, we injected mice in the right and left quadriceps with a total of 15 μg of purified plasmid C-E37997, E37997, C-EOPY-1 or EOPY-1 suspended in 100 μl of normal saline three times at weeks 0, 3 and 6. Each group contained five mice. We collected sera and spleen 10 days after the last injection. In monkey experiments, we injected 3–4 year old rhesus macaques weighing 3–4 kg intramuscularly in the anterior quadriceps with either 20 μg of VLPs in 1 mL PBS (VLP group) or 1 mL PBS alone (control group) at weeks 0, 4 and 24. Each group contained six monkeys. To measure antibody titers, we collected blood on days −14, 0, 10, 28, 38, 56, 70, 161 and 178. We challenged the monkeys (n=3 per group, randomly selected from each group) with 1010 PFU of CHIKV (strain LR2006 OPY-1) 15 weeks after the final immunization by intravenous injection. We collected blood to measure viremia at 0, 6, 24, 48, 72, 96, 120 and 168 hours, and sacrificed the monkeys 168 h after challenge. All animal experiments were reviewed and approved by the Animal Care and Use Committee, VRC, National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/vrc) in accordance with relevant federal guidelines and regulations.
We used a HiTrap™ Protein G HP column (GE Healthcare) and a Melon Gel IgG Purification Kit (Pierce) for antibody purification. We dialyzed purified IgG three times against PBS. We administered 2 mg of purified IgG (from approximately 200 μl of serum) into each recipient IFN-α/βR-/- mouse by tail vein injection 24 h before challenge. The challenge consisted of 30 PFU of CHIKV (strain LR2006 OPY-1), administered by intradermal injection.
All results are expressed as means ± s.e.m. We analyzed the data with unpaired two-tailed t tests (Prism 5).
Additional methods are described in the Supplementary Methods.
We thank K. Nagashima (Image Analysis Laboratory, SAIC-Frederick, Inc., National Cancer Institute) for help with electron microscopy and J.D. Yoder for initiating cryoelectron microscopy reconstruction. We also thank A. Tislerics and J. Stein for help with manuscript preparation, B. Hartman for graphic arts, and members of the Nabel lab for helpful discussions. We thank R. Seder and D.D. Pinschewer (Department of Pathology and Immunology, University of Geneva) for their kind gift of IFN-α/βR-/- mice, A. Ault, J.-P. Todd, A. Zajac, C. Chiedi and D. Gordon for plaque assay and processed animal blood samples, J. Greenhouse for RT-PCR assay, B.W. Finneyfrock, T. Jenkins and A. Dodson for animal sampling and care, K. Foulds, M. Donaldson and M. Roederer for monkey sample procedures, and J. Lee for preparing materials. This research was supported by the Intramural Research Program of the Vaccine Research Center, National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health.
The authors declare that they have no competing financial interests.